Zacks downgraded shares of Avino Silver & Gold Mines Ltd. (NYSEMKT: ASM) from a neutral rating to an underperform rating in a research note released on Wednesday morning. They currently have $1.50 target price on the stock. On Friday shares of Avino Silver & Gold Mines Ltd. (NYSEMKT: ASM) closed at $1.69.
Puma Biotechnology, Inc. (NYSE:PBYI) said that Ghana Football Association (GFA) has agreed an extension of its partnership with PUMA. Puma Biotechnology, Inc. (NYSE:PBYI) in last trading activity increased 9.37% to close at $215.52. Company weekly performance is 6.82% while its quarterly performance stands at -2.66%. Puma Biotechnology, Inc. (NYSE:PBYI) is -22.85% away from its 52 week high.
On 15 January Elbit Systems Ltd. (NASDAQ:ESLT) announced that it was awarded Israeli Ministry of Defense (IMOD) contracts, in a total amount of approximately $117 million, for the supply of Command, Control, Computer, Communications and Intelligence (C4I) systems and communications systems. Most of the contracts will be performed over a six-year period. On last trading day Elbit Systems Ltd. (NASDAQ:ESLT) moved down -0.69% to close at $62.30. Its volatility for the week is 1.38% while volatility for the month is 1.44%. ESLT’s sales growth for past 5 years was 2.10% and its EPS growth for past 5 years was -2.00%. Elbit Systems Ltd. (NASDAQ:ESLT) monthly performance is 8.90%.
On 14 January Pharmacyclics Inc. (NASDAQ:PCYC) announced that full year 2014 U.S. net product revenue for IMBRUVICA is expected to be approximately $492 million. The company expects U.S. net product revenue of approximately $1 billion for IMBRUVICA in 2015. Pharmacyclics Inc. (NASDAQ:PCYC) has 0.40% insider ownership while its institutional ownership stands at 76.10%. In last trading activity company’s stock closed at $145.51.
On 5 January Alliqua, Inc. (NASDAQ:ALQA) announced that it has signed a group purchasing agreement for regenerative skin grafting products with Premier, Inc. This agreement offers Premier alliance members access to Alliqua BioMedical’s regenerative skin graft products, including Biovance® Human Amniotic Membrane Allograft, at specially negotiated pricing and terms. On last trading day Alliqua, Inc. (NASDAQ:ALQA) moved down -2.85% to close at $5.12. Its volatility for the week is 6.33% while volatility for the month is 7.55%. ALQA’s EPS growth for past 5 years was -10.90%. Alliqua, Inc. (NASDAQ:ALQA) monthly performance is 29.79%.